AFMD(Delisted)
Affimed·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AFMD
Affimed N.V.
A clinical-stage immuno-oncology company that develops therapeutics for cancer
Gottlieb-Daimler-Straβe 2, 68165 Mannheim, Germany
--
Affimed N.V. was established as a holding company in the Netherlands in May 2014. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of highly targeted cancer immunotherapies. The development of the company's product candidates in the field of immuno-oncology represents an innovative approach to cancer therapy that aims to harness the body's own immune system against tumor cells.
Company Financials
EPS
AFMD has released its 2024 Q2 earnings. EPS was reported at -1.09, versus the expected -0.99, missing expectations. The chart below visualizes how AFMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AFMD has released its 2024 Q3 earnings report, with revenue of 172.75K, reflecting a YoY change of -91.68%, and net profit of -16.87M, showing a YoY change of 34.55%. The Sankey diagram below clearly presents AFMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
